A carregar...
Anti-HER2/neu Antibody Reduces Chemotherapy-Induced Ovarian Toxicity—From Bench to Bedside
Background: Trastuzumab, a humanized anti-human epidermal growth factor receptor 2 (HER2/neu) antibody, is considered a standard treatment in addition to chemotherapy in the adjuvant setting for HER2/neu-positive breast cancer, yet its impact on fertility and ovarian reserve remains obscure. We aime...
Na minha lista:
| Publicado no: | Biomedicines |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7762209/ https://ncbi.nlm.nih.gov/pubmed/33297351 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/biomedicines8120577 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|